| Trial ID: | L4385 |
| Source ID: | NCT01876849
|
| Associated Drug: |
Exenatide
|
| Title: |
An Open-Label Study Examining the Long-Term Safety of Exenatide Given Twice Daily to Patients With Type 2 Diabetes Mellitus
|
| Acronym: |
|
| Status: |
COMPLETED
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Type 2 Diabetes Mellitus
|
| Interventions: |
DRUG: exenatide
|
| Outcome Measures: |
Primary: Long-term safety of twice-daily exenatide treatment, as defined by the occurrence of adverse events., Visits for this study occur at 6-mo (±2 wk) intervals until exenatide is approved for marketing., 128 weeks (average treatment period) |
|
| Sponsor/Collaborators: |
Sponsor: AstraZeneca | Collaborators: Eli Lilly and Company
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE3
|
| Enrollment: |
275
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT
|
| Start Date: |
2003-12
|
| Completion Date: |
2008-07
|
| Results First Posted: |
|
| Last Update Posted: |
2015-02-24
|
| Locations: |
Research Site, Renton, Washington, United States
|
| URL: |
https://clinicaltrials.gov/show/NCT01876849
|
